Can Creon Cause Diarrhea?
No, Creon (pancrelipase) does not typically cause diarrhea—rather, it is prescribed to treat diarrhea and steatorrhea caused by exocrine pancreatic insufficiency (EPI). However, diarrhea has been reported as an adverse reaction in postmarketing surveillance, though it is not a common side effect in clinical trials 1.
Understanding the Context
Creon's Primary Purpose
Creon is pancreatic enzyme replacement therapy (PERT) designed to reduce diarrhea and steatorrhea in patients with EPI 2. According to the 2023 AGA Clinical Practice Update, diarrhea is actually a symptom of untreated EPI that PERT aims to control 2.
Clinical Trial Evidence
In controlled trials, diarrhea was not listed among the most common adverse reactions (≥4%) in patients with cystic fibrosis or chronic pancreatitis/pancreatectomy 1. The most common adverse reactions in these studies were:
- Vomiting (6%)
- Dizziness (4%)
- Cough (4%)
Postmarketing Reports
The FDA label notes that diarrhea has been identified during postapproval use as part of "gastrointestinal disorders" 1. However, because these reactions are reported voluntarily from an uncertain population size, it's difficult to establish a definitive causal relationship.
Clinical Interpretation
When Diarrhea Occurs on Creon
If a patient develops diarrhea while taking Creon, consider these possibilities:
1. Inadequate Dosing
- The dose may be insufficient to control EPI symptoms
- Initial dosing should be at least 40,000 lipase units per meal and 20,000 units per snack 2
- Titrate up to a maximum of 2,500 lipase units/kg per meal or 10,000 units/kg per day 2
2. Incorrect Administration
- Creon must be taken during meals, not before or after 2
- Capsules should not be crushed or chewed 1
- For multiple capsules, spread them throughout the meal 3
3. Alternative Diagnosis The 2023 AGA guidelines emphasize that multiple conditions can mimic or coexist with EPI 2:
- Celiac disease
- Small intestinal bacterial overgrowth (SIBO)
- Bile acid diarrhea
- Inflammatory bowel disease (Crohn's disease)
- Infectious causes (e.g., giardiasis)
These alternative diagnoses should be considered when a patient with EPI does not respond to PERT 2.
Clinical Approach to Diarrhea on Creon
Step 1: Verify Proper Use
- Confirm patient takes Creon during meals with adequate liquid 1
- Ensure capsules are swallowed whole (not crushed/chewed) 1
- Verify dosing is adequate for meal size and fat content 2
Step 2: Optimize PERT Therapy
- Increase dose if steatorrhea persists (up to maximum safe limits) 2
- Consider adding PPI or H2-blocker if using non-enteric coated preparations 2
- Assess dietary fat intake and meal patterns 2
Step 3: Re-evaluate Diagnosis
If diarrhea persists despite optimized PERT:
- Perform fecal elastase testing (can be done while on PERT) 2
- Consider testing for celiac disease, SIBO, bile acid diarrhea 2
- Evaluate for infectious causes 2
Important Safety Considerations
Serious Gastrointestinal Concerns
While diarrhea itself is not a primary concern with Creon, call the doctor immediately if the patient develops 1:
- Severe or unusual abdominal pain
- Bloating
- Trouble passing stool
- Nausea or vomiting with diarrhea
These could indicate fibrosing colonopathy, a rare but serious bowel disorder associated with excessive PERT dosing (>6,000 lipase units/kg per meal in children <12 years) 1.
Expected Therapeutic Effects
Successful PERT treatment should result in 2:
- Reduction in stool frequency
- Improved stool consistency (more formed stools)
- Decreased fat excretion
- Weight gain and improved nutritional status
Studies demonstrate that Creon significantly reduces stool frequency (from 10.8 to 5.2 stools per day) and improves stool consistency compared to placebo 4, 5.
Bottom Line
Creon treats diarrhea rather than causes it. If diarrhea occurs or persists on Creon, the most likely explanations are inadequate dosing, improper administration, or an alternative/concurrent diagnosis requiring evaluation. The evidence consistently shows that properly dosed PERT improves diarrhea and steatorrhea in patients with EPI 4, 5, 6.